Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen Provides Free Simplified Dementia Screening Tool to Medical Institutions
July 25, 2013
- Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance
July 24, 2013
- Novartis Launches Diovan OD Tablets, Sales Reps Find Promotion Difficult
July 24, 2013
- Astagraf XL, Tacrolimus Extended-Release Capsules, Approved in US: Astellas
July 24, 2013
- Kyowa Kirin Files Poteligeo for PTCL, CTCL in Japan
July 23, 2013
- Toho University Prof. Nakamura Says Prasugrel Promising in Preventing Platelet Clotting
July 22, 2013
- AD Treatment Lu AE58054 Improves Cognitive Performance in PII Study: Otsuka Pharmaceutical
July 22, 2013
- AD Biomarker TOMM40 Favorable in Detecting AD Risk: Takeda
July 19, 2013
- Xtandi Share May Increase as Second-Line Drug in US, Ranks Top as Third-Line Drug: Kantar Health
July 19, 2013
- Teribone’s Sales Growing Fast, Owing to High Demand of Drugs Promoting Bone Formation: Asahi Kasei Pharma President
July 19, 2013
- 60% Generic Share Target Is Highly Achievable: Daiichi Sankyo Espha President Yoshiwaka
July 19, 2013
- Novartis to Share Ex-Employee Hearing Info, Says “Gravely Concerned” about Media Reports
July 18, 2013
- Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
- BIKEN, JPRI to Merge in April
July 18, 2013
- MTPC to Strengthen Vaccine Development through Merger with Canadian Biotech Company Medicago
July 18, 2013
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- GSK Withdraws COPD Indication from NDA for ICS/LABA Combination Drug in Japan
July 17, 2013
- Astellas Launches Anticancer Agent Xtandi in UK
July 16, 2013
- Hisamitsu Initiates Domestic PII Study of Long-Acting Transdermal Allergic Rhinitis Treatment
July 16, 2013
- Manipulation of Data Cannot Be Confirmed Based on Results of University’s Investigation: Novartis Pharma
July 16, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…